193 related articles for article (PubMed ID: 31650904)
1. Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia.
Eljaaly K; Botaish A; Bahobail F; Almehmadi M; Assabban Z; Thabit AK; Alraddadi B; Aljabri A; Alqahtani N; Aseeri MA; Hashim A; Torres A
J Chemother; 2020 Feb; 32(1):1-6. PubMed ID: 31650904
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials.
Ashy N; Alharbi L; Alkhamisi R; Alradadi R; Eljaaly K
J Infect Chemother; 2022 Aug; 28(8):1148-1152. PubMed ID: 35523718
[TBL] [Abstract][Full Text] [Related]
3. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
[TBL] [Abstract][Full Text] [Related]
5. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
[TBL] [Abstract][Full Text] [Related]
6. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia.
Jang TN; Liu CY; Wang FD; Yang SP; Fung CP
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Apr; 55(4):302-6. PubMed ID: 7796357
[TBL] [Abstract][Full Text] [Related]
8. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.
Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M
Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of empiric macrolides versus fluoroquinolones in community-acquired pneumonia associated with atypical bacteria: A meta-analysis.
Basilim A; Wali H; Rabaan AA; Eljaaly K
Respir Med Res; 2022 Nov; 82():100931. PubMed ID: 35905552
[TBL] [Abstract][Full Text] [Related]
11. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
[TBL] [Abstract][Full Text] [Related]
12. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials.
Li XM; Wang FC; Yang F; Jin YH
Chin Med J (Engl); 2013; 126(11):2179-85. PubMed ID: 23769580
[TBL] [Abstract][Full Text] [Related]
13. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
[TBL] [Abstract][Full Text] [Related]
14. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
15. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
[TBL] [Abstract][Full Text] [Related]
17. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group.
Chien SM; Pichotta P; Siepman N; Chan CK
Chest; 1993 Mar; 103(3):697-701. PubMed ID: 8449054
[TBL] [Abstract][Full Text] [Related]
18. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
20. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
